ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
10 Jan 2025 11:31

VCredit (2003 HK): Offer Now Open. IFA Says Not Fair. Not Even Close

Unless you have some strong opinion on the back-end - I don't - this is an avoid. No one will tender into this Offer. Nothng to see here.

Logo
484 Views
Share
09 Jan 2025 09:04

Rio Tinto/Arcadium: Home Straight After CFIUS Nod

The key reg approvals have been satisfied. Any pullback on Trump blustering is a buy.  Trading at a ~3.2% gross return for the Aussie line. That's...

Logo
459 Views
Share
08 Jan 2025 12:53

GAPack (468 HK): Additional Thoughts On Mengniu Selling

China Mengniu can simply sell its entire stake to XJF; but not above the Offer Price. So what's stopping Mengniu if they appear to be selling down?

Logo
642 Views
Share
08 Jan 2025 10:26

PA Gooddoctor (1833 HK)'s Unconditional MGO

If in for the arb and opting for scrip, I 'd have exited, or exiting my initial buy-in. If in for the arb and took cash, I'd also would have...

Logo
657 Views
Share
bearishWH Group
07 Jan 2025 13:21

WH Group (288 HK): Smithfield's IPO Doc Now Out

WHG could surprise the market with a higher than expected IPO price. I doubt it. Even applying a high-end value for Smithfield of ~US$10bn, a ~38%...

Logo
583 Views
Share
x